Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Gains from Sales and Divestitures: 2013-2024

  • Coherus Oncology's Gains from Sales and Divestitures rose 118.10% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year increase of 118.10%. This contributed to the annual value of $2.8 million for FY2024, which is 118.10% up from last year.
  • Latest data reveals that Coherus Oncology reported Gains from Sales and Divestitures of $2.8 million as of Q4 2024, which was up 118.10% from $1.3 million recorded in Q4 2023.
  • Coherus Oncology's Gains from Sales and Divestitures' 5-year high stood at $2.8 million during Q4 2024, with a 5-year trough of $223,767 in Q4 2020.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $1.3 million (2023), whereas its average is $1.6 million.
  • Data for Coherus Oncology's Gains from Sales and Divestitures shows a peak YoY skyrocketed of 118.10% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Coherus Oncology's Gains from Sales and Divestitures stood at $223,767 in 2020, then surged by 108.22% to $465,930 in 2021, then surged by 73.17% to $806,854 in 2022, then spiked by 58.75% to $1.3 million in 2023, then surged by 118.10% to $2.8 million in 2024.
  • Its last three reported values are $2.8 million in Q4 2024, $1.3 million for Q4 2023, and $806,854 during Q4 2022.